We are live on ! Find out more
HVC

Healthcare Value Capital Portfolio holdings

AUM $50.7M Turnover 28.57%
1-Year Est. Return 24.72%
This Fund
S&P 500
This Quarter Est. Return
+20.6%
1 Year Est. Return
+24.72%
3 Year Est. Return
+18.99%
5 Year Est. Return
+98.49%
10 Year Est. Return
–
AUM
$63.1M
AUM Growth
-$19.4M
Cap. Flow
-$10.3M
Cap. Flow %
-16.33%
Top 10 Hldgs %
86.31%
Holding
30
New
4
Increased
1
Reduced
3
Closed
10
Avg Time Held Equity + Options
1.3 years
Top 10 Avg Time Held Equity + Options
1.1 years
Top 20 Avg Time Held Equity + Options
0.9 years
Avg Time Held Equity only
1.6 years
Top 10 Avg Time Held Equity only
1.4 years
Top 20 Avg Time Held Equity only
1.5 years

Top Buys

Rank Stock Value
1
GILD icon
Gilead Sciences
GILD
+$2.03M
2
AMRN icon
Amarin Corp
AMRN
+$1.26M

Top Sells

Rank Stock Value
1
ANIP icon
ANI Pharmaceuticals
ANIP
+$9.07M
2
AORT icon
Artivion
AORT
+$3.78M
3
SGNT
SAGENT PHARMACEUTICALS INC COM STK (DE)
SGNT
+$749K

Sector Composition

Rank Sector Weight
1 Healthcare 84.51%
2 Miscellaneous 15.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
ANIP icon
1
ANI Pharmaceuticals
ANIP
$1.66B
$13.3M 21.02%
200,000
-145,000
-42% -$9.07M
2015 Q2
5 quarters
ASRT icon
2
DELISTED
Assertio
ASRT
$8.74M 13.84%
5,833
– –
2015 Q4
3 quarters
PFE icon
3
Pfizer
PFE
$169B
$5.93M 9.39%
184,450
– –
2014 Q1
10 quarters
DGX icon
4
Quest Diagnostics
DGX
$25.9B
$5.6M 8.87%
66,208
– –
2013 Q2
13 quarters
AMRI
5
DELISTED
Albany Molecular Research Inc
AMRI
$4.99M 7.91%
302,400
– –
2014 Q1
10 quarters
QLTI icon
6
DELISTED
QLT Inc
QLTI
$4.44M 7.04%
2,157,200
– –
2014 Q4
7 quarters
ANIP icon
7
PUT
ANI Pharmaceuticals
ANIP
$1.66B
$3.32M 5.26%
50,000
– –
2016 Q2
1 quarter
ARLZ
8
DELISTED
Aralez Pharmaceuticals Inc.
ARLZ
$2.79M 4.42%
575,000
– –
2016 Q1
2 quarters
GILD icon
9
CALL
Gilead Sciences
GILD
$194B
$2.77M 4.39%
+35,000
New +$2.84M
2016 Q3
0 quarters
AORT icon
10
Artivion
AORT
$1.06B
$2.64M 4.18%
150,000
-250,000
-63% -$3.78M
2014 Q3
8 quarters
GILD icon
11
Gilead Sciences
GILD
$194B
$1.98M 3.13%
+25,000
New +$2.03M
2016 Q3
0 quarters
AMAG
12
PUT
DELISTED
AMAG Pharmaceuticals
AMAG
$1.84M 2.91%
75,000
-30,000
-29% -$750K
2016 Q2
1 quarter
AMRN icon
13
Amarin Corp
AMRN
$239M
$1.44M 2.27%
+22,500
New +$1.26M
2016 Q3
0 quarters
CYTK icon
14
Cytokinetics
CYTK
$8.61B
$918K 1.45%
100,000
– –
2014 Q4
7 quarters
TWM icon
15
ProShares UltraShort Russell2000
TWM
$70.3M
$721K 1.14%
1,250
– –
2014 Q1
10 quarters
VIRX icon
16
CALL
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$656K 1.04%
4,286
+3,572
+500% +$504K
2015 Q1
6 quarters
KITE
17
PUT
DELISTED
Kite Pharma, Inc.
KITE
$480K 0.76%
+8,600
New +$479K
2016 Q3
0 quarters
ZGNX
18
DELISTED
Zogenix, Inc.
ZGNX
$364K 0.58%
31,850
– –
2015 Q1
6 quarters
SEEL icon
19
DELISTED
Seelos Therapeutics, Inc. Common Stock
SEEL
– –
0
– –
2016 Q1
2 quarters
FCSC
20
DELISTED
Fibrocell Science Inc.
FCSC
$106K 0.17%
9,851
– –
2014 Q1
10 quarters
AORT icon
21
CALL
Artivion
AORT
$1.06B
– –
-50,000
Closed -$591K –
ASRT icon
22
CALL
DELISTED
Assertio
ASRT
– –
-1,667
Closed -$1.96M –
SPY icon
23
PUT
State Street SPDR S&P 500 ETF Trust
SPY
$806B
– –
-75,000
Closed -$15.7M –
TWM icon
24
CALL
ProShares UltraShort Russell2000
TWM
$70.3M
– –
-2,500
Closed -$1.74M –
VIXY icon
25
CALL
ProShares VIX Short-Term Futures ETF
VIXY
$241M
– –
-63
Closed -$916K –
1
2

Similar funds

C
Castlelake Minneapolis, Minnesota $48.5M AUM 87.77% 1-Year Est. Return
CC
Cedar Capital Barrington, Illinois $54.9M AUM 33.3% 1-Year Est. Return
FCOI
FirstMark Capital OF II New York $44.1M AUM 18.15% 1-Year Est. Return
FCOI
FirstMark Capital OF I New York $43.1M AUM 6.31% 1-Year Est. Return
BI
BCBSM Inc Eagan, Minnesota $42.4M AUM 0.4% 1-Year Est. Return
KC
Kelso & Company New York $42.3M AUM
SCIM
Spring Creek Investment Management Philadelphia, Pennsylvania $42.3M AUM 31.86% 1-Year Est. Return
MCP
Moab Capital Partners Southampton, New York $41M AUM 33.21% 1-Year Est. Return

Healthcare Value Capital's Q3 2016 Portfolio in Review

As of Q3 2016, Healthcare Value Capital held 30 positions worth $63.1M, down 23% from $82.5M the previous quarter. Its ten largest holdings account for 86% of the portfolio.

Healthcare Value Capital withdrew a net $10.3M in Q3 2016, closing 10 positions and reducing 3 holdings. Its most notable exit was SAGENT PHARMACEUTICALS INC COM STK (DE), an estimated $749K position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, up from 64% a quarter earlier, followed by Miscellaneous.

Against the trend, Healthcare Value Capital opened a new position in Gilead Sciences worth $1.98M.

  • Healthcare Value Capital's largest Q3 2016 buy was Gilead Sciences: 25,000 shares worth $1.98M.
  • Healthcare Value Capital's biggest Q3 2016 reduction was ANI Pharmaceuticals, cutting an estimated $9.07M.
  • Healthcare Value Capital fully exited SAGENT PHARMACEUTICALS INC COM STK (DE) in Q3 2016, selling an estimated $749K.
  • Healthcare Value Capital's ten largest holdings make up 86% of its $63.1M portfolio in Q3 2016.
  • Healthcare Value Capital opened 4 new positions and closed 10 in Q3 2016.
  • Healthcare Value Capital's portfolio value fell 23% quarter-over-quarter to $63.1M.

Based on Healthcare Value Capital's 13F filing for Q3 2016, filed 10 Nov 2016.